BOSTON, July 14, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the first ...
We studied 123 neonates with atresias of the gastrointestinal tract at different levels to assess the role of amniotic fluid in the growth and development of the gastrointestinal tract. Our hypothesis ...
Currently, there is no FDA-approved treatment for biliary atresia, a rare pediatric liver disease. Albireo Pharma announced that the Food and Drug Administration (FDA) has granted Orphan Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback